Chemical Component Summary

NameAXITINIB
IdentifiersN-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-2H-indazol-6-yl]sulfanyl]benzamide
FormulaC22 H18 N4 O S
Molecular Weight386.47
Typenon-polymer
Isomeric SMILESCNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)[nH]nc2c1
InChIInChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
InChIKeyRITAVMQDGBJQJZ-FMIVXFBMSA-N

Chemical Details

Formal Charge0
Atom Count46
Chiral Atom Count0
Chiral Atomsn/a
Bond Count49
Aromatic Bond Count22
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB06626 Different stereochemistry
NameAxitinib
Groups
  • approved
  • investigational
DescriptionAxitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta®, and if one previous systemic therapy for kidney cell cancer has failed, axitinib is indicated.
Synonyms
  • axitinib
  • axitinibum
Brand NamesInlyta
Affected OrganismHumans and other mammals
IndicationUsed in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
PharmacologyAxitinib prevents the progression of cancer by inhibiting angiogenesis and blocking tumor growth.
Mechanism of actionAxitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.
Route of administrationOral
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Azoles
  • Chemical Actions and Uses
  • Cytochrome P-450 CYP1A2 Substrates
ATC-CodeL01XE17
AHFS-Code10:00
CAS number319460-85-0
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682